Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now?
· finance.yahoo.com
Investors appear to have left Novo Nordisk behind as they focus on Eli Lilly; that could be a mistake.
The pharmaceutical industry is highly competitive and driven by innovation. Those two facts couldn't be on any clearer display than in the competition between N...